Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment primarily involves chemotherapy, often combined with PD-1/PD-L1 inhibitors or biomarker-directed therapies. In 2024, treatment options expanded with the first-in-class approvals of Akeso’s Kaitanni (cadonilimab) and Astellas’s Vyloy (zolbetuximab). The uptake of existing therapies and the expected launch of new treatments such as CARsgen’s CT041, Hengrui’s retlirafusp alfa, and SystImmune / Bristol Myers Squibb’s BL-B01D1 will result in substantial market growth over the next decade. In this report, we analyze how clinical and nonclinical factors—price dynamics, inclusion in China’s National Reimbursement Drug List, and the entry of generics or biosimilars—will influence the launch and uptake of new and existing therapies. Understanding the impact of these intersecting factors will be crucial to the success of current and future players in this highly competitive market.

Questions answered

• What is the diagnosed incidence of gastroesophageal cancer in China, and how are these patients treated today? Do treatment management strategies differ between urban and rural China?
• What are interviewed experts’ insights into current therapies and their views on the emerging treatments?
• What are the key unmet needs in the treatment of gastroesophageal cancer in China, according to interviewed experts?
• What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies in this market?

Primary research: Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists in China.

Epidemiology: Diagnosed incidence of gastroesophageal cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions.

Custom drug modeler: Integrated tool to input customized forecast assumptions (e.g., launch date, price)

Product description: China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy in China.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.
• Gauge the commercial outlook and impact of key market events.